(R)-Adibelivir
Based on 1 Customer Validation
(R)-Adibelivir ((R)-IM-250) is a blood-brain barrier-permeable HSV helicase-primase inhibitor. (R)-Adibelivir specifically inhibits the activity of the HSV UL5-UL52-UL8 helicase-primase complex. (R)-Adibelivir affects viral reactivation and significantly reduces the reactivation capacity of latent neuronal HSV reservoirs. (R)-Adibelivir can be used in studies related to herpes simplex virus infection, herpes encephalitis, neonatal herpes, and other related conditions.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 2305750-24-5
- Formula: C20H19F2N3O2S2
- Molecular Weight:435.51
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All DNA/RNA Synthesis Isoforms
More
Biological Activity
|
Helicase |
(R)-Adibelivir ((R)-IM-250) exhibits higher anti-HSV potency than prior helicase-primase inhibitors, remains active against HSV strains resistant to other helicase-primase inhibitors, and penetrates neural tissues effectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2305750-24-5
-
Appearance Solid
-
Molecular Weight 435.51
-
Formula C20H19F2N3O2S2
-
Color White to off-white
-
SMILES
FC(C=CC(F)=C1)=C1C(C=C2)=CC=C2CC(N(C3=NC(C)=C([S@](C)(=N)=O)S3)C)=O
-
Synonyms
(R)-IM-250
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (229.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sarvari G, et al. Structure, Function and Inhibition of Helicases Involved in Virus Infection. Biomolecules. 2026;16(2):273. Published 2026 Feb 9. [Content Brief]
[2]. Gege C, et al. Structural determinants of nervous system exposure of adibelivir (IM-250) and related herpes helicase-primase inhibitors across animal species. Antiviral Res. 2025;243:106271. [Content Brief]
[3]. Bay C, et al. A UPLC-MS/MS assay for the quantification of the novel viral helicase-primase drug candidate adibelivir (IM-250) in human specimen. J Chromatogr B Analyt Technol Biomed Life Sci. 2026;1275:124995. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2962 mL | 11.4808 mL | 22.9616 mL | 57.4040 mL |
| 5 mM | 0.4592 mL | 2.2962 mL | 4.5923 mL | 11.4808 mL | |
| 10 mM | 0.2296 mL | 1.1481 mL | 2.2962 mL | 5.7404 mL | |
| 15 mM | 0.1531 mL | 0.7654 mL | 1.5308 mL | 3.8269 mL | |
| 20 mM | 0.1148 mL | 0.5740 mL | 1.1481 mL | 2.8702 mL | |
| 25 mM | 0.0918 mL | 0.4592 mL | 0.9185 mL | 2.2962 mL | |
| 30 mM | 0.0765 mL | 0.3827 mL | 0.7654 mL | 1.9135 mL | |
| 40 mM | 0.0574 mL | 0.2870 mL | 0.5740 mL | 1.4351 mL | |
| 50 mM | 0.0459 mL | 0.2296 mL | 0.4592 mL | 1.1481 mL | |
| 60 mM | 0.0383 mL | 0.1913 mL | 0.3827 mL | 0.9567 mL | |
| 80 mM | 0.0287 mL | 0.1435 mL | 0.2870 mL | 0.7175 mL | |
| 100 mM | 0.0230 mL | 0.1148 mL | 0.2296 mL | 0.5740 mL |
- (R)-Adibelivir
- 2305750-24-5
- (R)-IM-250
- HSV
- DNA/RNA Synthesis
- neuronal latent herpes viral reservoir
- herpes simplex virus infections
- herpes encephalitis
- HSV strains
- HSV helicase-primase inhibitor
- blood-brain barrier
- neonatal herpes
- HSV UL5-UL52-UL8 helicase-primase complex
- blood-nerve barrier
- Inhibitor
- inhibitor
- inhibit